A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in children and adults
Latest Information Update: 16 Apr 2019
At a glance
- Drugs TCR alphabeta-CD19-depleted peripheral blood stem cell therapy (Primary)
- Indications Acute myeloid leukaemia; Aplastic anaemia; Haematological malignancies; Hodgkin's disease; Leukaemia; Lysosomal storage diseases; Metabolic disorders; Multiple myeloma; Myelodysplastic syndromes; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma; Sickle cell anaemia; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms TCRalpha/beta-Haplo2010
- Sponsors Miltenyi Biotec GmbH
- 04 Dec 2018 Status changed to completed as per results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 12 Dec 2017 Results (n=30) assessing one year safety and efficacy follow-up, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology